Primary Outcome Measures: | |
1. |
Disease Free Survival (DFS) rate [ Time Frame: 5 years after tisagenlecleucel infusion ]
DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause. |
Secondary Outcome Measures: | |
1. |
Percentage of participants who are disease free without allogeneic stem cell transplant (SCT) [ Time Frame: 12 months after last infusion ]
Minimal Residual Disease (MRD) negative remission (complete remission (CR) or Complete remission with incomplete blood count recovery CRi)) at Month 12 without SCT after tisagenlecleucel infusion. |
2. |
Overall Survival [ Time Frame: 8 years ]
Time from tisagenlecleucel infusion to the death due to any cause |
3. |
Percentage of participants achieving MRD negative CR or CRi at Month 3 [ Time Frame: 3 months after the tisagenlecleucel infusion. ]
MRD negative status as determined by central laboratory using multi-parameter flow cytometry |
4. |
Percentage of participants with in CR or CRi with persistent B-cell aplasia over time post tisagenlecleucel infusion [ Time Frame: 8 years ]
Absolute lymphocyte CD19 count of >50/uL |
5. |
Percentage of participants who have tisagenlecleucel product successfully manufactured over the total number of subjects enrolled for the age ≥1 year and < 3 years [ Time Frame: 8 years ]
Success in manufacturing of tisagenlecleucel dose for patients who are ≥1 year and <3 years as respective time points. |
6. |
Pediatric Quality of Life (PedsQL) [ Time Frame: 5 years ]
Patient reported outcome to assess quality of life in patients aged 8 and above. The 23 items PedQL (Pediatrics Quality of Life Inventory) measure core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. Items measured include 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items). Each item is measured on a 5 point Likert scale with 0 indicating "never" and 4 indicating "almost always". The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 5=25, and 4=0. A higher score indicates better health-related quality of life (HRQoL). |
7. |
European Quality of Life 5 dimensions (EQ-5D-3L & EQ-5D-Y)) [ Time Frame: 5 years ]
Patient reported outcome to assess health status in patients aged 8 and above. The EQ-5D (European Quality of Life -5 Dimensions) measures a wide range of health conditions and treatments; it is composed of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (EQ-visual analogue scale [EQ-VAS]) that records the patient's self-rated overall health state. Respondents rate each of these 5 dimensions from "no problem", "some problem," or "extreme problem". The EQ-VAS records the respondents' self-related health on a vertical, visual analogue scale. The range for EQ-VAS is from 0 (=the worst health you can imagine) to 100 (=the best health you can imagine). |
8. |
Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Detection test [ Time Frame: 5 years ]
Speed of performance (mean of the log10 transformed reaction times for correct responses) |
9. |
Impact of tisagenlecleucel on cognitive functioning usingComputerized neurocognitive assessment: Identification test [ Time Frame: 5 years ]
This test measures the speed of performance (mean of the log10 transformed reaction times for correct responses) |
10. |
Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Groton Maze Learning test [ Time Frame: 5 years ]
This test looks at the total number of errors made in attempting to learn the hidden pathways during a single session. |
11. |
Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: One Back test [ Time Frame: 5 years ]
This test measures the accuracy of performance (arcsine transformation of the square root of the percentage of correct responses). The test also measures the speed of performance (mean of the log10 transformed reaction times for correct responses). |
12. |
Impact of tisagenlecleucel on cognitive functioning usingComputerized neurocognitive assessment: One card learning test [ Time Frame: 5 years ]
This test measures the accuracy of performance (arcsine transformation of the square root of the proportion of correct responses). |
13. |
Percentage of participants with pre-existing antibodies [ Time Frame: 8 years ]
Prevalence of immunogenicity |
14. |
Percentage of participants with anti-m CAR19 antibodies post infusion with tisagenlecleucel and % of patients without measureable anti-mCAR19 antibodies [ Time Frame: 8 years ]
Incidence of immunogenicity |
15. |
Percentage of patients that have measureable anti-mCAR19 antibodies above patient specific cut-point (reported as a %) pre and post tisagenlecleucel infusion categorized by Day 28 response [ Time Frame: 8 years ]
Impact of immunogenicity on clinical response |
16. |
tisagenlecleucel transgene concentration [ Time Frame: 8 years ]
Transgene concentration as detected by qPCR in target tissue |
17. |
Expression of tisagenlecleucel [ Time Frame: 8 years ]
Summary of tisagenlecleucel CAR-positive viable T cells measured by flow cytometry in target tissue |
18. |
Persistence of CAR (reported as copies/ug) categorized by the time to B-cell recovery (recovery < 3 months, >3 months to < 6months, > 6 months) [ Time Frame: 8 years ]
Relationship between B-cell recovery and transgene levels |
19. |
Cmax; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration (% or copies/μg) |
20. |
Tmax; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The time to reach maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days) |
21. |
AUC0-29d and 84d; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The AUC from time zero to day 29 and 84 or other disease assessment days, in peripheral blood (% or copies/μg x days ) |
22. |
AUC0-Tmax; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The AUC from time zero to Tmax in peripheral blood (% or copies/μg x days) |
23. |
T1/2; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood |
24. |
Clast; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The last observed quantifiable concentration in peripheral blood (% or copies/μg) |
25. |
Tlast; cellular kinetic parameter of tisagenlecleucel [ Time Frame: 8 years ]
The time of last observed quantifiable concentration in peripheral blood (days) |
26. |
Impact of tisagenlecleucel dose on day 29 response [ Time Frame: 8 years ]
Clinical response summarized by quartile of administered doses |
27. |
AUC 0 - 29d; cellular kinetic parameter of tisagenlecleucel [ Time Frame: Day 29 ]
Impact of tisagenlecleucel exposure on day 29 response; The AUC from time zero to day 29 in peripheral blood (% or copies/μg x days ) |
28. |
Cmax: cellular kinetic parameter of tisagenlecleucel [ Time Frame: Day 29 ]
Impact of tisagenlecleucel exposure on day 29 response; The maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration (% or copies/μg) |
29. |
Tmax: cellular kinetic parameter of tisagenlecleucel [ Time Frame: Day 29 ]
Impact of tisagenlecleucel exposure on day 29 response; The time to reach maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days) |
30. |
T1/2: cellular kinetic parameter of tisagenlecleucel [ Time Frame: Day 29 ]
Impact of tisagenlecleucel exposure on day 29 response; The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood |